{"id":6387,"date":"2019-11-13T12:27:05","date_gmt":"2019-11-13T06:57:05","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6387"},"modified":"2025-05-08T12:10:11","modified_gmt":"2025-05-08T06:40:11","slug":"beta-thalassemia","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia","title":{"rendered":"Beta-Thalassemia Pharmacological Therapies"},"content":{"rendered":"\n<p>Thalassemia is a group of inherited blood disorders that are a result of defects or mutations in the genes. The defect results in defective or less production of the haemoglobin, thus hampering the transport of the oxygen to all the body parts. <\/p>\n\n\n\n<p>The most common form of the thalassemia is Beta-Thalassemia.\nIt causes a decrease in the production of the normal haemoglobin (Hb A), which\nis the principal form of the Haemoglobin.&nbsp;\n<\/p>\n\n\n\n<p>The highest <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/thalassemia-epidemiology-forecast\">Beta-Thalassemia prevalence<\/a><\/strong> occurs in the Mediterranean region, parts of North and West Africa, the Middle East, the Indian subcontinent and the Southern Far East and Southeast Asia, together known as the \u2018thalassemia belt\u2019. Iran, located in the Middle East, is one of the countries where the \u03b2-globin gene mutations are particularly frequent.<\/p>\n\n\n\n<p>The disorder is only visible in the\npopulation who inherit defected copies of the gene from both the parents. In\ncase of inheritance of one gene, the person would be called a carrier of the\ndisorder. According to a study by Sanctis V. D et al (2017), approximately 1.5%\nof the global population are heterozygotes (carriers) of the \u03b2-thalassemia.<\/p>\n\n\n\n<p>The main aim of the Beta-thalassemia\ntreatment is mainly to suppress erythroid expansion. The pharmacological\nBeta-thalassemia treatment comprises regular blood-transfusion. However, this\ncan put patients at a risk of iron overload, transfusion reactions, and giving\nrise to red blood cells antibodies which makes the transfusion difficult. <\/p>\n\n\n\n<p>Thus, bone marrow transplant and cord blood transplant are the only potential <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-thal-market\">beta-thalassemia cure<\/a><\/strong>. Additionally, cord blood transplant is a consideration for parents who already have a child with beta-thalassemia and later identify an HLA-compatible foetus in a subsequent pregnancy.<\/p>\n\n\n\n<p>Scientists across the globe are working on\nfinding a standard and potential cure for the Beta-Thalassemia. The hope for\nthe Beta-Thalassemia treatment is the rectification of the mutated gene by\neither insertion of deletion of the required one. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Thalassemia is a group of inherited blood disorders that are a result of defects or mutations in the genes. The defect results in defective or less production of the haemoglobin, thus hampering the transport of the oxygen to all the body parts. The most common form of the thalassemia is Beta-Thalassemia. It causes a decrease [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6390,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[109,6860,1906],"industry":[17225],"therapeutic_areas":[17238,17233,17234],"class_list":["post-6387","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-beta-thalassemia","tag-blood-disorders","tag-thalassemia","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-hematological-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Beta-Thalassemia Pharmacological Therapies - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"The hope for the Beta-Thalassemia treatment is the rectification of the mutated gene by either insertion or deletion of the required...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beta-Thalassemia Pharmacological Therapies - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"The hope for the Beta-Thalassemia treatment is the rectification of the mutated gene by either insertion or deletion of the required...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-13T06:57:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T06:40:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/09182314\/Beta-Thalassemia-Pharmacological-Therapies.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Beta-Thalassemia Pharmacological Therapies - DelveInsight Business Research","description":"The hope for the Beta-Thalassemia treatment is the rectification of the mutated gene by either insertion or deletion of the required...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia","og_locale":"en_US","og_type":"article","og_title":"Beta-Thalassemia Pharmacological Therapies - DelveInsight Business Research","og_description":"The hope for the Beta-Thalassemia treatment is the rectification of the mutated gene by either insertion or deletion of the required...","og_url":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-11-13T06:57:05+00:00","article_modified_time":"2025-05-08T06:40:11+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/09182314\/Beta-Thalassemia-Pharmacological-Therapies.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia","url":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia","name":"Beta-Thalassemia Pharmacological Therapies - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/09182314\/Beta-Thalassemia-Pharmacological-Therapies.jpg","datePublished":"2019-11-13T06:57:05+00:00","dateModified":"2025-05-08T06:40:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The hope for the Beta-Thalassemia treatment is the rectification of the mutated gene by either insertion or deletion of the required...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/beta-thalassemia"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/09182314\/Beta-Thalassemia-Pharmacological-Therapies.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/09182314\/Beta-Thalassemia-Pharmacological-Therapies.jpg","width":772,"height":482,"caption":"Beta Thalassemia Pharmacological Therapies"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/09182314\/Beta-Thalassemia-Pharmacological-Therapies-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">beta-thalassemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">blood disorders<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Thalassemia<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">beta-thalassemia<\/span>","<span class=\"advgb-post-tax-term\">blood disorders<\/span>","<span class=\"advgb-post-tax-term\">Thalassemia<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Nov 13, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Nov 13, 2019 12:27 pm","modified":"Updated on May 8, 2025 12:10 pm"},"featured_img_caption":"Beta Thalassemia Pharmacological Therapies","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6387"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6387\/revisions"}],"predecessor-version":[{"id":31914,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6387\/revisions\/31914"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6390"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6387"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6387"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}